Boulos & Cooper Pharmaceuticals Pty., Ltd.

Boulos & Cooper Pharmaceuticals Pty., Ltd.

19 Caroona Ave., Unit 1, Hove
Adelaide, Australia
Phone: +61 431 150 538
About the Company

Boulos & Cooper Pharmaceuticals Pty., Ltd. is an Australian start-up company incorporated in October 2013. The company is commercializing technology where novel antibiotics effective against a wide range of Gram-positive bacteria were identified. This new class of non-toxic antimicrobials (and antioxidants) is effective against Gram +ve bacteria including C. difficile and MRSA with an MIC of 2 µg/mL for Ramizol® and 0.125 µg/mL for Chlopam®. The work has attracted media attention with coverage on Channel Ten News Perth in 2012.

The antibiotics activate a novel antibiotic target, the bacterial mechanosensitive ion channel of large conductance (MscL). Mechanosensitive channels have evolved the ability to sense mechanical tension on the membrane and convert it into an electrochemical response. As such, they act as gatekeepers, rescuing bacterial cells from lysis in high osmotic environments. The use of in-silico modeling and docking experiments using the bacterial mechanosensitive ion channel membrane protein MscL as a target has given birth to this new class of antibiotics which are in the preclinical stages of drug development. Our candidates show low toxicity and no mutagenicity as determined by the AMES test.

In Feb 2012, the Company was evaluated at AUD $33 million and we are currently open to investments.